|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Cost of sales | |||||
| Impairment of intangible asset | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Selling, general and administrative | |||||
| Research and development | |||||
| Acquired in-process research and development | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Non-operating income (expense): | |||||
| Interest income | |||||
| Interest expense | |||||
| Charges associated with convertible senior notes | |||||
| Other income (expense), net | |||||
| Total non-operating income (expense) | |||||
| Loss before taxes | |||||
| Income tax (benefit) provision | |||||
| Net loss | |||||
| Basic net loss per share (in dollar per share) | |||||
| Diluted net loss per share (in dollar per share) | |||||
| Weighted average shares outstanding used to compute basic net loss per share | |||||
| Weighted average shares outstanding used to compute diluted net loss per share | |||||
Loading...